Dr Lam is recognized globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committees of PARAGON, DELIVER, FINEARTS-HF and EMPEROR-Preserved trials contributed to the first approved treatments for HFpEF to date. She was appointed to the 2021-2022 European Society of Cardiology Heart Failure Guidelines Task Force and has published >700 articles in journals including NEFM, JAMA, Lancet, Circulation and European Heart Journal; being recognized as Clarivate’s Highly cited Researcher 2021-2024 in Clinical Medicine. She also serves as Deputy Editor for JACC. In the field of MedTech, Dr. Lam is co-founder of Us2.ai, an award-winning startup dedicated to the automation of the fight against heart disease by applying artificial intelligence to echocardiography (ultrasound of the heart).